EUVIMEDEUVIMED entdecken
Systematische Übersicht

Tranexamic acid in dacryocystorhinostomy. A systematic review

Angeliki Sevasti Kollatou

Aristotle University of Thessaloniki · 01.01.2025

DOI: 10.26262/heal.auth.ir.366396 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 01.01.2025. Verfasst von Angeliki Sevasti Kollatou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tranexamic acid (TXA) is an antifibrinolytic drug that prevents the plasminogen’s conversion into plasmin, thus suppressing the enzymatic breakdown of fibrin and as a result, hemostasis is preserved in various surgical fields. Dacryocystorhinostomy (DCR) is a frequently executed surgical procedure to manage nasolacrimal duct obstruction (NLDO), where intraoperative bleeding remains a significant challenge, potentially affecting visualization and prolonging operative time. However, the overall impact of TXA in DCR remains uncertain. The objective of this systematic review is to examine the current research concerning the role of TXA in DCR, focusing on its impact on intraoperative bleeding, surgical duration, and surgical field clarity. A systematic review was executed in compliance with PRISMA guidelines. PubMed/MEDLINE, Cochrane, and Google Scholar databases were used up to March 30, 2025, and randomized controlled trials (RCTs) assessing TXA use in DCR were identified. Studies were screened and selected based on predefined eligibility criteria. Four RCTs involving a total of 286 patients were included. Three studies compared intravenous or topical TXA to normal saline (placebo), and one compared TXA to hydralazine and remifentanil. Two studies, one with intravenous and one with topical application of TXA, exhibited a statistically significant decrease in both intraoperative hemorrhage and surgical duration. However, according to one trial, no significant difference was detected in the assessed outcomes, and the study that compared TXA to alternative agents found greater efficacy with hydralazine and remifentanil. Surgical field clarity and surgeon satisfaction improved with TXA in some cases, but results were not statistically significant. A low risk of bias was identified in one trial and of some concern in the others, largely attributed to subjective outcome measures. TXA may be effective in decreasing intraoperative hemorrhage and surgical time during DCR, with both topical and intravenous routes showing potential benefits. However, evidence is limited, with small sample sizes, variable outcome measures, and subjective assessments. Further research is required to enhance the reliability of findings and establish the most effective dosing schemes.

Schlagwörter

tranexamic aciddacryocystorhinostomynasolacrimal duct obstructionintraoperative bleedingantifibrinolytic agentsoperative timehydralazineremifentaniltopical tranexamic acidintravenous tranexamic acid

Zitieren

APA

Kollatou, A. S. (2025). Tranexamic acid in dacryocystorhinostomy. A systematic review. Aristotle University of Thessaloniki. https://doi.org/10.26262/heal.auth.ir.366396

Vancouver

Kollatou AS. Tranexamic acid in dacryocystorhinostomy. A systematic review. Aristotle University of Thessaloniki. 2025. doi:10.26262/heal.auth.ir.366396

BibTeX
@article{Kollatou2025,
  author = {Kollatou, Angeliki Sevasti},
  title = {Tranexamic acid in dacryocystorhinostomy. A systematic review},
  journal = {Aristotle University of Thessaloniki},
  year = {2025},
  doi = {10.26262/heal.auth.ir.366396}
}
Kostenlos starten →